Brokerages expect that Erytech Pharma SA (NASDAQ:ERYP) will report ($0.80) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Erytech Pharma’s earnings. The business is scheduled to report its next earnings report on Monday, January 1st.
On average, analysts expect that Erytech Pharma will report full year earnings of ($2.82) per share for the current year. For the next fiscal year, analysts anticipate that the business will report earnings of ($2.71) per share. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Erytech Pharma.
Several brokerages have weighed in on ERYP. ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th.
Erytech Pharma Company Profile
ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
Recommended Story: Trading Stocks – What are percentage gainers?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.